Nuance Pharma announced that the first participant has been dosed in the REACH Phase III clinical trial of STG320 (Actair), a house dust mite (HDM) allergen immunotherapy originally developed by Stallergenes Greer, for the treatment of HDM‑associated allergic rhinitis in China. The milestone advances the program toward potential registration of Actair in one of the world’s largest allergy markets.
Trial Initiation
| Item | Detail |
|---|---|
| Sponsor | Nuance Pharma |
| Trial Name | REACH |
| Phase | Phase III |
| Investigational Product | STG320 (Actair) |
| Indication | House dust mite–associated allergic rhinitis |
| Region | China |
| Key Milestone | First participant dosed – announced 30 Oct 2026 |
| Primary Endpoint / Sample Size / Timeline | Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: STG320, a house dust mite allergen immunotherapy designed to induce disease‑modifying immune tolerance to HDM allergens rather than merely suppress symptoms.
- Origin: Originally developed by Stallergenes Greer, a global leader in allergen immunotherapy.
- Commercial Track Record: Already commercialized in 21 countries and regions under brand names including Actair, Orylmyte, and Aitmyte, with further market expansion underway.
- Disease Context: Allergic rhinitis is among the most prevalent chronic conditions in China, and house dust mite is a leading perennial trigger; allergen immunotherapy remains the only treatment approach targeting the underlying immune cause, representing significant unmet need versus symptomatic antihistamines and intranasal corticosteroids.
China Partnership & Regulatory Pathway
- Sept 2025: Nuance Pharma entered an exclusive, long‑term collaboration with Stallergenes Greer for the development and registration of Actair in China, with Nuance Pharma retaining subsequent commercialization rights.
- Jan 2026: Actair received marketing approval in Macao, China.
- May 2026: Actair launched in the Hainan Boao Lecheng Pilot Zone through an early access program.
- May 2026: China’s National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application for Actair.
- Oct 2026: First participant dosed in the pivotal REACH Phase III trial – the key registration‑enabling study for the mainland China market.
Market Impact & Outlook
- Registration Momentum: Dosing of the first participant in REACH marks the transition from regulatory preparation to pivotal clinical execution, putting Actair on the path toward a potential NMPA registration for HDM allergic rhinitis.
- Multi‑Gateway China Entry: The combination of Macao approval, Hainan Boao Lecheng early access, and a mainland Phase III program gives Nuance Pharma a layered market‑entry strategy ahead of full national registration.
- De‑Risked Asset: With an established safety and efficacy profile from 21 countries and regions of commercial use, STG320 carries lower development risk than a novel molecular entity.
- Commercial Upside: Successful completion of REACH would position Nuance Pharma to introduce a disease‑modifying immunotherapy into a large, underpenetrated Chinese allergy market currently dominated by symptom‑relief therapies.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial conduct, regulatory review timelines, and commercial expectations for STG320 (Actair) in China. Actual results may differ materially due to risks including trial enrollment and outcomes, NMPA review decisions, and competitive dynamics in the allergy immunotherapy market.-Fineline Info & Tech
